The Cali Fund was supposed to be the biodiversity economy's grand bargain: companies that profit from nature's genetic information voluntarily return 1% of profits — or 0.1% of revenue — to conservation in low-income countries. The target was $1bn annually. After 18 months, the fund's bank account holds $7,085. Three small biotech firms contributed. Zero major pharmaceutical companies have paid a cent. The numbers are almost satirical. Zero Carbon Analytics calculates that the top 15 pharmaceutical companies generated roughly $161bn in profits in 2025. A 1% contribution from those firms alone would yield $756m — nearly the entire annual target. Instead, those same companies paid shareholders 175 times more than their suggested Cali Fund contribution. The fund has attracted three donors: Prozomix ($5,000), TierraViva AI ($1,000), and E-Biom ($1,085), all small firms. Pharma's defence is procedural, not principled. The International Federation of Pharmaceutical Manufacturers and Associations argues the fund's blanket contribution model is flawed because not all medicines rely on digital sequence information (DSI), and the mechanism overlaps with existing national laws. This is a delay tactic dressed as a design critique. The industry isn't proposing an alternative payment structure — it's proposing continued non-payment while the architecture is debated indefinitely. The underlying extraction is structural. Advances in biotechnology mean genetic information from organisms worldwide is now digitised and stored in public databases, severing the physical link between a sample's country of origin and the company that profits from it. The Cali Fund was explicitly designed to close this loophole. But a voluntary mechanism aimed at an industry that spent decades fighting compulsory licensing for essential medicines was always going to produce this result. As Campaign for Nature's Brian O'Donnell put it: more money has been spent on meetings about the fund than exists in its coffers. The geopolitics are straightforward. Low-income countries — particularly those in the Global South with high biodiversity — are the source of genetic material that underpins drug discovery. Indigenous peoples and local communities, who were promised at least half the fund's distributions, are the ultimate cost-bearers of continued non-payment. The value chain runs from tropical forests and traditional knowledge to patent-protected blockbuster drugs, with the financial return flowing exclusively upward. Cop17 in Yerevan this week will put the fund back on the table, but the structural incentives haven't changed. The fund's own spokesperson acknowledged the total raised is "disappointing but not entirely surprising" and suggested comparable instruments take two to three years to scale. That framing treats the problem as one of awareness rather than incentive design. Pharma companies are fully aware of the fund — GSK's spokesperson explicitly acknowledged it and said they'd decide on contributions once more information was available. Awareness isn't the bottleneck. Enforcement is. The 20-year question is whether biodiversity finance will follow the carbon-offset playbook — voluntary pledges, perpetual shortfalls, and eventual crisis-driven regulation — or whether this failure is so immediate and total that it forces a mandatory mechanism sooner. The Cali Fund's current trajectory suggests the former. A $1bn annual target met by $7,000 in deposits is not a slow start. It is a proof of concept for why voluntary corporate conservation finance does not work.
